Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
51. |
ECCT/25/05/01 | Sparkle Study Site 1403 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive CrisesA phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 6. Gertrudes Children’s Hospital (Nairobi City county) |
18-12-2025 |
View |
52. |
ECCT/25/04/07 | Server migration Server Migration |
Principal Investigator(s) 1. Server Migration Server Migration Site(s) in Kenya Server Migration |
30-04-2025 |
View |
53. |
ECCT/25/04/03 | PRETERM AFRICA STUDY Pragmatic Evaluation of Therapies to Enhance Respiratory Management in Preterm Infants in Africa |
Principal Investigator(s) 1. Nayirat Mohamed Site(s) in Kenya 1. Coast General Teaching and Referral Hospital (Mombasa county) |
10-03-2026 |
View |
54. |
ECCT/25/03/07 | Sparkle - Site 1405 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Prof Videlis Nduba Site(s) in Kenya 1. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. Gertrudes Children’s Hospital (Nairobi City county) 6. Victoria Biomedical Research Institute (Kisumu county) |
16-09-2025 |
View |
55. |
ECCT/25/03/06 | Sparkle Study-Site 1404 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Godfrey Allan Otieno Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 6. Gertrudes Children’s Hospital (Nairobi City county) |
26-11-2025 |
View |
56. |
ECCT/25/03/05 | Sparkle Study -Site 1402 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. Site 1401: Victoria Biomedical Research Institute (Kisumu county) 2. Site 1402: Ahero Clinical trials Unit (Kisumu county) 3. Site 1403: International Cancer Institute (Uasin Gishu county) 4. Site 1404: Kondele Childrens Hospital (Kisumu county) 5. Site 1405: KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 6. Site 1406: Gertrude’s Children’s Hospital. (Nairobi City county) |
16-12-2025 |
View |
57. |
ECCT/25/04/01 | PHASE 2/3 OF SII-TCV(B) A PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY AND IMMUNE NON-INTERFERENCE OF A BIVALENT CONJUGATE VACCINE AGAINST SALMONELLA ENTERICA SEROVARS TYPHI AND PARATYPHI A IN HEALTHY INFANTS AGED 9 TO 12 MONTHS |
Principal Investigator(s) 1. WALTER OTIENO Site(s) in Kenya VICTORIA BIOMEDICAL RESEARCH INSTITUTE |
07-10-2025 |
View |
58. |
ECCT/25/03/04 | Ndovu RCT Investigating the optimal management of dolutegravir resistance: an open-label randomised controlled trial of maintaining dolutegravir or switch to ritonavir-boosted darunavir |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Kenyatta National Hospital (KNH) (Nairobi City county) 2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 3. Bomu Hospital (Mombasa county) |
14-07-2025 |
View |
59. |
ECCT/25/09/03 | PRESERVE Partial breast re-irradiation using ultra hypofractionation (PRESERVE) Phase 2 multi-institutional study |
Principal Investigator(s) 1. Angela Waweru Site(s) in Kenya Aga Khan University Hospital |
09-02-2026 |
View |
60. |
ECCT/25/07/06 | SASI Randomized Controlled Trial of Surfactant Administered via Supraglottic Airway Device (SALSA) Compared to Endotracheal Tube (InSurE) on Survival without Mechanical Ventilation in Preterm Neonates with Respiratory Distress Syndrome in Sub-Saharan Africa |
Principal Investigator(s) 1. Mary Waiyego Kariuki Site(s) in Kenya Kenyatta national Hospital |
31-10-2025 |
View |